proANP (1-98) ELISA

pproANP (1-98) ELISA/p
pimg alt=For Research Use Only src=http://www.alpco.com/img/ruo.gif align=absMiddle / For Research Use Only/p
div class=prod_head_infohr /
/div
div class=prod_spec_box
div class=prod_specbFormat:/b/div
div class=prod_spec_infoELISA / EIA/div
/div
div class=prod_spec_box
div class=prod_specSample Type:/div
div class=prod_spec_infoPlasma, Cell Culture, Urine/div
/div
div class=prod_spec_box
div class=prod_specbSample Size:/b/div
div class=prod_spec_info10 micro;l/div
/div
div class=prod_spec_box
div class=prod_specbSize:/b/div
div class=prod_spec_info96 Wells/div
/div
div class=prod_spec_box
div class=prod_specbRange:/b/div
div class=prod_spec_info0.63 - 10 nmol/l/div
/div
div class=prod_spec_box
div class=prod_specbSensitivity:/b/div
div class=prod_spec_info0.05 nmol/l/div
/div
div class=prod_spec_box
div class=prod_specbIncubation Time:/b/div
div class=prod_spec_info4 Hour/div
div class=prod_spec_info
pbSummary:/b/p
The proANP (1-98) ELISA is an enzyme immunoassay intended for the quantitative determination of proANP (1-98) in Plasma, Serum, Urine and Cell Culture supernatants. Atrial natriuretic peptide (ANP) is synthesized in atrial myocytes and is stored in secretory granules as a 126 amino acid prohormone . The most important stimulus for the release of the hormone into circulation is stretching of the cardiomyocyte fibres. Circulating levels of proANP (1-98) are typically measured because of its longer half-life and because they ar less sensitive to the pulsatile secretion of ANP. ProANP is discussed as a valuable marker for sepsis (Hoffmann U et al. Clin Lab. 2005;51:373-9), and for aid in heart failure risk stratification (Berger R et al. Eur J Clin Invest. 2005; 35:24-31).
pbLiterature References:/b/p
img src=http://www.alpco.com/img/black_bullet.gif alt= /a href=http://www.clas.org/jcla24-2.htmClerico A, DelRy S, Giannessi D, Trianni G, Rizza A, Botto N, and Biagini A. Evaluation and comparison of commercial immunoassay methods for the determination of N-terminal proANP in plasma and atrial cardiac tissue. J of Clin Ligand Assay. 2001; 24:112-118./abr /
br /
img src=http://www.alpco.com/img/black_bullet.gif alt= /a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieveamp;db=PubMedamp;list_uids=14633912amp;dopt=AbstractClerico A, and Emdin M. Diagnostic Accuracy and Prognostic Relevance of the Measurement of Cardiac Natriuretic Peptides: A Review. Clinical Chemistry. 2004; 50:1 33-50./abr /
br /
img src=http://www.alpco.com/img/black_bullet.gif alt= /a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieveamp;db=PubMedamp;list_uids=11405605amp;dopt=AbstractHammerer-Lercher A, Puschendorf B and Mair J. Cardiac Natriuretic Peptides: New Laboratory Parameters in Heart Failure Patients. Clin Lab. 2001; 47:265-277./abr /
br /
img src=http://www.alpco.com/img/black_bullet.gif alt= /a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieveamp;db=PubMedamp;list_uids=9539472amp;dopt=AbstractGlobits S, Frank H, Pacher B, Huelsmann M, and Pacher M. Atrial Natriuretic Peptide Release Is More Dependent on Atrial Filling Volume Than on Filling Pressure in Chronic Congestive Heart Failure Am Heart J. 1998 Apr;135(4):592-7. /abr /
br /
img src=http://www.alpco.com/img/black_bullet.gif alt= / Muuml;ller MM, and Griesmacher A. New Trends in Classification, Monitoring and Management of Cardiovascular Diseases. Berichte der Ouml;GKC. 2002; Jg. 25, 56 ndash; 62.br /
br /
img src=http://www.alpco.com/img/black_bullet.gif alt= /a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieveamp;db=pubmedamp;list_uids=10791374amp;dopt=medlineTroughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, and Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. THE LANCET. 2002; Vol 355, 1126-1130./abr /
br /
img src=http://www.alpco.com/img/black_bullet.gif alt= /a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieveamp;db=PubMedamp;list_uids=12766002amp;dopt=AbstractMueller T, Gegenhuber A, Poelz W, Haltmayer W. Comparison of the Biomedica NT-proBNP Enzyme Immunoassay and the Roche NT-proBNP Chemiluminescence Immunoassay: Implications for the Prediction of Symptomatic and Asymptomatic Structural Heart Disease. Clinical Chemistry. 2003; 49, No. 6, 976-979./abr /
br /
img src=http://www.alpco.com/img/black_bullet.gif alt= /a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieveamp;db=PubMedamp;list_uids=11499735amp;dopt=AbstractStanek B, Frey B, Hulsmann M, Berger R, Sturm B, Strametz-Juranek J, Bergler-Klein J, Moser P, Bojic A, Hartter E, Pacher R. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol. 2001 Aug; 38(2):436-42. /abr /
br /
pnbsp;/p
pnbsp;/p
/div
/div